BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35022811)

  • 1. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
    Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
    Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic susceptibility contrast perfusion-weighted and diffusion-weighted magnetic resonance imaging findings in pilocytic astrocytoma and H3.3 and H3.1 variant diffuse midline glioma, H3K27-altered.
    Kurokawa R; Kurokawa M; Baba A; Kim J; Srinivasan A; Moritani T
    PLoS One; 2023; 18(7):e0288412. PubMed ID: 37450487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion and diffusion-weighted imaging parameters: Comparison between pre- and postbiopsy MRI for high-grade glioma.
    Kurokawa R; Baba A; Kurokawa M; Capizzano A; Ota Y; Kim J; Srinivasan A; Moritani T
    Medicine (Baltimore); 2022 Sep; 101(35):e30183. PubMed ID: 36107564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T2-FLAIR mismatch sign and machine learning-based multiparametric MRI radiomics in predicting IDH mutant 1p/19q non-co-deleted diffuse lower-grade gliomas.
    Tang WT; Su CQ; Lin J; Xia ZW; Lu SS; Hong XN
    Clin Radiol; 2024 May; 79(5):e750-e758. PubMed ID: 38360515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
    Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
    J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T2-FLAIR Mismatch Sign in Pediatric Low-Grade Glioma.
    Wagner MW; Nobre L; Namdar K; Khalvati F; Tabori U; Hawkins C; Ertl-Wagner BB
    AJNR Am J Neuroradiol; 2023 Jul; 44(7):841-845. PubMed ID: 37348970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology.
    Foltyn M; Nieto Taborda KN; Neuberger U; Brugnara G; Reinhardt A; Stichel D; Heiland S; Herold-Mende C; Unterberg A; Debus J; von Deimling A; Wick W; Bendszus M; Kickingereder P
    Neurooncol Adv; 2020; 2(1):vdaa004. PubMed ID: 32642675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T2-FLAIR mismatch sign correlates with
    Ebiko Y; Tamura K; Hara S; Inaji M; Tanaka Y; Nariai T; Ishii K; Maehara T
    J Neurooncol; 2023 Aug; 164(1):257-265. PubMed ID: 37589920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium.
    Lee MD; Patel SH; Mohan S; Akbari H; Bakas S; Nasrallah MP; Calabrese E; Rudie J; Villanueva-Meyer J; LaMontagne P; Marcus DS; Colen RR; Balana C; Choi YS; Badve C; Barnholtz-Sloan JS; Sloan AE; Booth TC; Palmer JD; Dicker AP; Flanders AE; Shi W; Griffith B; Poisson LM; Chakravarti A; Mahajan A; Chang S; Orringer D; Davatzikos C; Jain R;
    Neuroradiology; 2023 Sep; 65(9):1343-1352. PubMed ID: 37468750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
    Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
    J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI.
    Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T
    Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
    Aliotta E; Dutta SW; Feng X; Tustison NJ; Batchala PP; Schiff D; Lopes MB; Jain R; Druzgal TJ; Mukherjee S; Patel SH
    J Neurooncol; 2020 Sep; 149(2):325-335. PubMed ID: 32909115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis.
    Park SI; Suh CH; Guenette JP; Huang RY; Kim HS
    Eur Radiol; 2021 Jul; 31(7):5289-5299. PubMed ID: 33409784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. There is an exception to every rule-T2-FLAIR mismatch sign in gliomas.
    Johnson DR; Kaufmann TJ; Patel SH; Chi AS; Snuderl M; Jain R
    Neuroradiology; 2019 Feb; 61(2):225-227. PubMed ID: 30565056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced MR imaging and
    Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.